Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite (ICU) Using Citrate- vs Acetate-based Dialysate

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

During intermittent hemodialysis (IHD), the occurrence of intradialytic hemodynamic instability (IHI) is frequent in ICU and impacted morbidity and mortality. Bicarbonate dialysate buffer improves hemodynamic tolerance compared to acetate dialysate buffer. However, bicarbonate dialysate buffer still contains a lower concentration of acetate, which could contribute to hemodynamic instability. Recently, citrate-based dialysate in bicarbonate hemodialysis instead of acetate have been proposed. They have the appropriate authorizations for routine use. The aim of this study is to compare acetate- vs citrate-based dialysate in terms of hemodynamic tolerance and effectiveness.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient ≥ 18 years old

• Patient hospitalized in an intensive care unit

• Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspected non-obstructive

• Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 seconds and/or cardiovascular SOFA ≥ 1 and/or lactatemia \> 2mmol/L)

• Indication for Extra Renal Replacement Therapy with IHD.

Locations
Other Locations
France
Centre Hospitalier Béthune
RECRUITING
Béthune
Centre Hospitalier Universitaire de Caen
NOT_YET_RECRUITING
Caen
Contact Information
Primary
Martin GÉRARD
mgerard@ch-bethune.fr
03.21.64.44.44
Backup
Christophe VINSONNEAU
cvinsonneau@ch-bethune.fr
03.21.64.44.44
Time Frame
Start Date: 2023-12-07
Estimated Completion Date: 2025-01-04
Participants
Target number of participants: 48
Treatments
Other: Control group
Using acetate-based dialysate
Experimental: Experimental group
Using citrate-based dialysate
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier de Bethune
Collaborators: CHU de Lille

This content was sourced from clinicaltrials.gov